Search
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigational[L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … [L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTerlipressin
go.drugbank.com/drugs/DB02638ApprovedInvestigational[A252672] The drug was first approved by the FDA in September 2022.[L43217] … Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor.
Pioglitazone
go.drugbank.com/drugs/DB01132ApprovedInvestigational[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence … [L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved
Anastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigational[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer
Aluminum hydroxide
go.drugbank.com/drugs/DB06723ApprovedInvestigationalIt is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin.
Mixtures: Neo Tigol Tab, EnoFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B. … [L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770]
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalIt neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms. … While AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13).
Insulin human
go.drugbank.com/drugs/DB00030ApprovedInvestigationalcells that the body is no longer able to produce insulin on its own. … Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin.
Products: Humulin N, Novolin NFosphenytoin
go.drugbank.com/drugs/DB01320ApprovedInvestigationalIt works by slowing down impulses in the brain that cause seizures. … Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Tetradecyl hydrogen sulfate (ester)
go.drugbank.com/drugs/DB11328ApprovedSodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins . Sodiu...